Dr. Tsao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2001 - 2004
- Indiana University School of MedicineResidency, Internal Medicine, 1998 - 2001
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2001 - 2026
- AZ State Medical License 2023 - 2026
- TN State Medical License 2023 - 2025
- OK State Medical License 2020 - 2024
- AL State Medical License 2023 - 2024
- GA State Medical License 2023 - 2024
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Start of enrollment: 2006 Aug 01
- BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Start of enrollment: 2006 Nov 01
- Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.Szlosarek, P., Creelan, B., Sarkodie, T., Nolan, L., Taylor, P., Olevsky, O., Grosso, F., Cortinovis, D., Chitnis, M., Roy, A., Gilligan, D., Kindler, H., Papadatos-Pa...> ;JAMA Oncology. 2024 Feb 15
- A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.Riely, G., Smit, E., Ahn, M., Felip, E., Ramalingam, S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussein, M.,...> ;Future Oncology. 2024 Feb 15
- Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From-Mutant NSCLC Informs Potential Therapeutic Targets.Bingnan Zhang, Whitney Lewis, C Allison Stewart, Benjamin B Morris, Luisa M Solis, Alejandra Serrano, Yuanxin Xi, Qi Wang, Elyse R Lopez, Kyle Concannon, Simon Heeke, ...> ;JTO Clinical and Research Reports. 2024 Feb 1
- Join now to see all
Lectures
- Changing the Concurrent Chemotherapy-Radiation Paradigm: Can We Replace Chemotherapy with...ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothel...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- Systemic treatment for unresectable malignant pleural mesotheliomaTsao AS, Vogelzang N
http://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma
UpToDate, Wolters Kluwer Health - 2013-04-15
Press Mentions
- ECOG-ACRIN Research Highlights at ASCO 2022May 27th, 2022
- New Mesothelioma Immunotherapy Clinical Trial Opens at MD AndersonMay 11th, 2022
- Raffit Hassan, MD, on Immunotherapy's Inroads in Malignant Pleural MesotheliomaMay 6th, 2022
- Join now to see all
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: